🤓 This Key Trend Is Ending – How to Prepare Now

Good morning. Over the last two years, employers have had a strong demand for employees...

It's the monthly jobs numbers today and they're not going to be pretty and will be possibly the tip of the iceberg as we head into May.

Good morning. Over the last two years, employers have had a strong demand for employees. Vacancies have exceeded those looking for jobs. And that allowed many to switch roles, and get into higher paying positions. That trend, now known as the "Great Resignation," is nearing an end. Last week, the Federal Reserve noted that there was a "real imbalance" in wage bargaining. And that raising interest rates to slow down the overheating economy would do much to rebalance that situation. More importantly, the past few weeks have seen a number of companies announce layoffs and workplace reductions. These rising job losses are showing that the economy is in a recessionary stance. Traders need to remain cautious. But as companies reduce their headcount and costs go down, they're setting up to be more profitable on the next economic upswing. That leaves plenty of trading opportunities on the long and short side of the market for months to come. Now here's the rest of the news: Sponsored Content Invest In This Biotech Company Solving A $240B Problem Every year, over 600M patients suffering from osteoarthritis spend $240 billion on painkillers and other palliative solutions to the cartilage damage caused by this debilitating disease. These "band-aid" therapies are temporary and do not treat the root cause of osteoarthritis. Enter Cytonics. This private biotech startup has harnessed the therapeutic potential of a naturally occurring blood protein, called "A2M," to reverse cartilage deterioration in arthritic joints. Their first FDA approved A2M-based therapy has successfully treated over 8,000 patients, proving the therapeutic efficacy of A2M, and restoring patients' quality of life. Backed by Johnson & Johnson and the NIH, Cytonics is developing a genetically engineered A2M variant that is more potent than the natural form. This lead drug candidate, "CYT-108," has been proven to restore up to 80% of cartilage damage caused by osteoarthritis in preclinical studies. Cytonics' first-in-in-class CYT-108 will enter Phase 1 clinical trials later this year. Invest in Cytonics as they blaze toward their second FDA drug approval, and before this private biotech goes public. MARKETS DOW 30,483.13 -0.15% S&P 3,759.89 -0.13% NASDAQ 11,053.08 -0.15% *As of market close • Stocks closed lower on Wednesday, but closed well off the morning lows • Oil sank 3.9 percent, closing at $105.24 per barrel. • Gold traded flat, going for $1,840 per ounce • Cryptocurrencies were slightly down, with Bitcoin at $20,086 at the market close. Today's TOP TIPS Buy Companies Doing This for Shareholders Right Now There are two main ways companies can reward shareholders. One way is to pay a growing dividend from rising cash flows over time. Another way is to buy back shares when the company's valuation is compellingly low. Some companies can do both, provided they don't overpay to buy back shares. With many stocks down right now, a few companies are setting up for better returns when the market sentiment turns bullish again with increased buybacks. » FULL STORY Insider Trading Report: Tilly's (TLYS) Michael Henry, CFO at Tilly's (TLYS), recently picked up 4,000 shares. The buy increased his stake by 16 percent, and came to a total cost of just under $29,000. This follows up on a 6,005 share buy from the director a few days before. This marks the first insider buy at the company since September 2020. Insiders were active buyers during the Covid selloff, and then have generally been sellers of shares in the past two years after shares rallied higher. » FULL STORY Unusual Options Activity: Pinterest (PINS) Shares of online board Pinterest (PINS) have shed 75 percent of their value in the past year. One trader sees the chance for a further decline in the coming few days. That's based on the July 1 $15 puts. With 8 days until expiration, 19,778 contracts traded compared to a prior open interest of 116, for a 171-fold rise in volume on the trade. The buyer of the puts paid $0.10 to get into the trade. » FULL STORY IN OTHER NEWS • Powell Committed to Continuing Rate Hikes Federal Reserve Chairman Jerome Powell stated before Congress yesterday that the central bank needs compelling evidence that inflation is slowing down before it changes course on its interest rate hikes. Powell notes that the bank is committed to getting inflation back to a 2 percent target rate, a substantial drop from the current rate of 8.6 percent. • Biden Asks Congress for Gas Tax Holiday President Biden is asking Congress to suspend federal taxes on gasoline and diesel fuel for three months. Federal taxes amount to 18.4 cents per gallon of gas and 24.4 cents for diesel. A few lawmakers, including former President Obama, have stated that such a tax holiday would be a short-term "gimmick." • UK Inflation Tops 9 Percent Inflation rates in the United Kingdom have topped 9.1 percent, based on May data. The UK now has the highest inflation rate among G7 nations, and is a slight increase from 9 percent in April. Economists expect the rate to continue rising in the coming months. • Daimler Truck Warns on Supply Chains Daimler Truck, the world's largest tuck manufacturer, is warnings on supply chain pressures that are slowing the production of thousands of vehicles. The costs of energy and raw materials are also soaring due to inflation, and also adding to expenses. At the moment, the company reports having as many as 10,000 trucks only missing one or two parts idling at factories. • Uniswap Acquires Genie Startup Uniswap is acquiring Genie, an NFT marketplace aggregator for an undisclosed sum. Uniswap acts as a decentralized platform that allows users to swap a wide variety of tokens, and the buy will add NFT functionality to the mix. Genie allows users to access NFTs across a variety of marketplaces. S&P 500 MOVERS TOP DVA  5.957% CLX  5.19% MRNA 4.677% NFLX 4.669% DHI 4.535% BOTTOM MO 9.19% FCX 7.964% MRO 7.229% APA 7.063% COP 6.265% Quote of the Day We don't see a U.S. or global recession in '22 or '23 in our base case, but it's clear that the risks of a hard landing are rising. Even if the economy does slip into a recession, however, it should be a shallow one given the strength of consumer and bank balance sheets. - A UBS note on why the economy may enter into a recession this year or next, but why it would likely prove a shallow one. Sponsored Content Invest In This Biotech Company Solving A $240B Problem Every year, over 600M patients suffering from osteoarthritis spend $240 billion on painkillers and other palliative solutions to the cartilage damage caused by this debilitating disease. These "band-aid" therapies are temporary and do not treat the root cause of osteoarthritis. Enter Cytonics. This private biotech startup has harnessed the therapeutic potential of a naturally occurring blood protein, called "A2M," to reverse cartilage deterioration in arthritic joints. Their first FDA approved A2M-based therapy has successfully treated over 8,000 patients, proving the therapeutic efficacy of A2M, and restoring patients' quality of life. Backed by Johnson & Johnson and the NIH, Cytonics is developing a genetically engineered A2M variant that is more potent than the natural form. This lead drug candidate, "CYT-108," has been proven to restore up to 80% of cartilage damage caused by osteoarthritis in preclinical studies. Cytonics' first-in-in-class CYT-108 will enter Phase 1 clinical trials later this year. Invest in Cytonics as they blaze toward their second FDA drug approval, and before this private biotech goes public. Not sure the best way to get started? Follow these simple steps to hit the ground running. › Step #1 - Get These FREE Reports: Warren Buffett's Top 5 Stocks | 10 Great Stocks Under $10 | 7 High Yield Dividend Stocks › Step #2 - Join Our Premium Advisory: The Next Superstock › Step #3 - Claim Your Free Copy Of: Big Book Of Chart Patterns | How to Trade Weekly Options For Weekly Income We just wanted to take a moment and say thank you so much for being part of our family! We are dedicated to teaching people how to make the world a better place so we can all thrive, together. We love sharing stories and featuring past learners who have applied our teachings and changed their situations. It's our passion to build a strong community centered around fun and mindset! We love to discover extraordinary and useful tools and share them with the world! We create a space where people can discover how to enjoy their lives by simply choosing to learn. Every day we are building and strengthening partnerships with our customers and clients and we do so in the most ethical way possible. We particularly love working with artisans, makers, and small businesses because through their passion and their craft they help make the world a better place.. Without all of you we wouldn't be able to do what we do on a daily basis and for that we say thank you. We've been living our dream for many years now and that wouldn't be possible without every single one of you. The idea of going from a typical nine to five life to a life of freedom doesn't seem real to most people, but we want you to know it is definitely possible. We've done it. You have the power to control your life, your actions, and what you choose to focus on. We're here to help you along that journey to achieve whatever goals you set out for yourself. However, we also care about keeping you and your privacy safe. We are committed to advising you of the right to your privacy. We strive to provide a safe and secure user experience. Our Privacy Policy explains how we collect, store and use personal information, provided by you on our website. It also explains how we collect and use non-personal information. By accessing and using our website, you explicitly accept, without limitation or qualification, the collection, use and transfer of the personal information and non-personal information in the manner described in this Privacy Policy. Please read this Policy carefully, as it affects your rights and liabilities under the law. If you disagree with the way we collect and process personal and non-personal information, please do not use this website. This Policy applies to this website as well as all webpages Company hosts. It regulates the processing of information relating to you and grants both of us various rights with respect to your personal data. It also informs you of how to notify us to stop using your personal information. We are located in the United States of America. You may be located in a country that has laws which are more restrictive about the collection and use of your personal information. However, by using our website, you agree to waive the more restrictive laws and agree to be governed by the laws of the United States of America. If you wish to view our privacy policy, you can find it below. Nothing in this email should be considered personalized financial advice. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing The Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions. As defined in the United States Securities Act of 1933 Section 27(a), as amended in the Securities Exchange Act of 1934 Section 21(e), statements in this communication which are not purely historical are forward-looking statements and include statements regarding beliefs, plans, intent, predictions or other statements of future tense. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

This email was sent to edwardlorilla1986.paxforex@blogger.com by editor@tradingtips.com TradingTips.com | 3435 Ocean Park Blvd. Suite 107-334 Santa Monica, CA 90405 Manage Subscriptions | report SPAM